Biohaven Ltd. (NYSE:BHVN), a global clinical-stage biopharmaceutical company focused on the discover

Enrollment complete in pivotal Phase 2/3 study evaluating opakalim in focal epilepsy (RISE3); top-li

Biohaven Ltd. (NYSE:BHVN) shares fell Monday after Bank of America Securities (BofA) downgraded the

Biohaven (BHVN) shares fall as BofA downgrades the stock to Underperform, citing a risky profile ahe

U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 1% on Mon

US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrol

B of A Securities analyst Jason Gerberry downgrades Biohaven (NYSE:BHVN) from Neutral to Underper

BHV-1300 is the first MoDE extracellular protein degrader, a novel small molecule IgG1, 2 and 4 degr

BHV-1300 is the first MoDE™ extracellular protein degrader to enter a pivotal trial, pioneering a ne

Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company f

Biohaven Ltd. (NYSE: BHVN) ("Biohaven") a global clinical-stage biopharmaceutical company fo

HC Wainwright & Co. analyst Douglas Tsao reiterates Biohaven (NYSE:BHVN) with a Neutral and m

Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discove

Morgan Stanley analyst Terence Flynn maintains Biohaven (NYSE:BHVN) with a Overweight and lowers

RBC Capital analyst Leonid Timashev maintains Biohaven (NYSE:BHVN) with a Outperform and lowers t

https://www.sec.gov/Archives/edgar/data/1935979/000162828026029834/biohavens-3asr.htm

Citigroup analyst Samantha Semenkow maintains Biohaven (NYSE:BHVN) with a Buy and raises the pric

Phase 2 study in obesity, evaluating treatment with once-weekly and once-monthly taldefgrobep alfa a

TD Cowen analyst Tyler Van Buren maintains Biohaven (NYSE:BHVN) with a Buy and raises the price t

Biohaven shares rose in premarket trading after Xenon's Phase 3 epilepsy study showed strong sei

HC Wainwright & Co. analyst Douglas Tsao maintains Biohaven (NYSE:BHVN) with a Neutral and lo

RBC Capital analyst Leonid Timashev maintains Biohaven (NYSE:BHVN) with a Outperform and raises t

Biohaven (NYSE:BHVN) reported quarterly losses of $(1.21) per share which missed the analyst consens

RBC Capital analyst Leonid Timashev upgrades Biohaven (NYSE:BHVN) from Sector Perform to Outperfo

Biohaven Ltd. shares surged 3.42% in after-hours trading following an SEC filing that detailed inves

Reports positive early clinical experience from first and only clinically validated, extracellular p

Morgan Stanley analyst Terence Flynn maintains Biohaven (NYSE:BHVN) with a Overweight and lowers

Biohaven shares are flat after the company announced its Phase 2 proof-of-concept study of BHV-7000

(Editor’s note: The future prices of benchmark tracking ETFs and the headline were updated in the st

Biohaven's Phase 2 study with BHV-7000 in MDD did not meet its primary endpoint of reducing depr

HC Wainwright & Co. analyst Douglas Tsao reiterates Biohaven (NYSE:BHVN) with a Neutral and m

US stock futures slightly lower. Stocks to watch: NVIDIA, Dynavax, Sobr Safe, Davis Commodities, Bio

Biohaven shares fell 16.19% in after-hours trading Wednesday after its Phase 2 depression drug trial

The company considers the depression subgroup analyses as hypothesis generating but based upon strat

Biohaven Ltd. (NYSE:BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company fo

HC Wainwright & Co. analyst Douglas Tsao downgrades Biohaven (NYSE:BHVN) from Buy to Neutral

UBS analyst Ashwani Verma downgrades Biohaven (NYSE:BHVN) from Buy to Neutral and lowers the pric

JP Morgan analyst Tessa Romero maintains Biohaven (NYSE:BHVN) with a Overweight and lowers the pr

Morgan Stanley analyst Terence Flynn maintains Biohaven (NYSE:BHVN) with a Overweight and lowers

Citigroup analyst Samantha Semenkow maintains Biohaven (NYSE:BHVN) with a Buy and lowers the pric